ERBB2 and breast cancer: However, the randomized phase III ACE-Breast-02 trial, comparing ARX788 to lapatinib plus capecitabine in HER2-positive advanced breast cancer, reported similar rates of any-grade and grade ≥3 TRAEs between treatment arms.